Perspective Therapeutics, based in Seattle, is a biotechnology company focused on developing radiopharmaceuticals for cancer treatment using the alpha-emitting isotope 212Pb. Their programs for melanoma and neuroendocrine tumors are in Phase I/IIa trials.